Table 3.

Outcomes with combination chemotherapy in metastatic head and neck Ca

Study	Agents	Response rates	Median overall survival in months (m)
Jacobs et al. [16]	CDDP	18 %	8 m
	Vs
	CDDP/MTX/Leucovorin	33 %	8 m
Drelichman et al. [17]	MTX	16 %	6 m
	Vs
	CDDP/Bleo/Oncovin	24 %	6 m
Williams et al. [18].	MTX	16 %	7.7 m
	Vs
	CDDP/Bleo/Vinblastine	24 %	7.2 m
Jacobs et al. [19]	5-Fu	13 %	6.1 m
	CDDP	17 %	5.0 m
	5-Fu/CDDP	32 %	5.5 m
Clavel et al. [21]	5- Fu/CDDP	31 %	6.1 m
	Vs
	CDDP/Oncovin/Bleo/MTX(CABO)	34 %	8.2 m

CDDP cisplatin, MTX methotrexate, Bleo(B) bleomycin, Oncovin(O) vincristine, 5-Fu 5fluorouracil